UHRF1(ubiquitin-like with PHD and Ring finger domains 1)是一种维持DNA甲基化修饰的表观遗传调控因子,在胚胎发育和肿瘤发生发展及预后中发挥重要作用。研究鉴定了受UHRF1调控的差异表达基因,并对基因参与的细胞功能、代谢途径和疾...UHRF1(ubiquitin-like with PHD and Ring finger domains 1)是一种维持DNA甲基化修饰的表观遗传调控因子,在胚胎发育和肿瘤发生发展及预后中发挥重要作用。研究鉴定了受UHRF1调控的差异表达基因,并对基因参与的细胞功能、代谢途径和疾病相关通路进行分析。提取UHRF1敲低细胞(MCF-7/shRNA-UHRF1)和对照组细胞(MCF-7/shRNA-Scramble)的RNA进行RNA-Seq测序,利用DESeq2软件对差异表达基因进行鉴定,并通过qRTPCR对部分基因进行验证。利用Gene ontology(GO)功能聚类、Kyoto Encylopedia of Genes and Genomes(KEGG)代谢通路富集分析、Disease ontology(DO)疾病聚类分析等方法分析差异基因的潜在功能。研究共鉴定出2926个受UHRF1调控的差异表达基因,与对照组相比,shRNA-UHRF1细胞中有1453个基因下调表达,1473个基因上调表达。GO和KEGG分析显示,差异表达基因主要参与细胞代谢、免疫调节、信号传导、心血管疾病和肿瘤发生等。DO功能富集分析显示这些基因参与癌症和神经性疾病。研究结果表明,表观遗传调控因子UHRF1介导的DNA甲基化可在转录水平上调控基因的差异表达,为UHRF1参与调控相关信号通路提供数据支持。展开更多
Mechanism functions and kinetic parameters of AlOOH（boehmite or diaspore） dissolving in sodium hydroxide solution were researched.The mixture of boehmite or diaspore and caustic solution was scanned by high-pressure...Mechanism functions and kinetic parameters of AlOOH（boehmite or diaspore） dissolving in sodium hydroxide solution were researched.The mixture of boehmite or diaspore and caustic solution was scanned by high-pressure differential scanning calorimetry（DSC） instrument with heating rate of 10 ℃/min,and differential equation method was used to analyse the DSC curves,combining with iterative method and linear least square method.The most probable mechanism functions for both boehmite or diaspore and caustic solution reactions were logically selected from 30 types of non-isothermal kinetics differential equations,according to the calculated results obtained by Matlab program.The most probable differential mechanism function of boehmite dissolving in caustic solution is f（α）=1-α,which reveals the first-order reaction with apparent activation energy of 79.178 kJ/mol and the preexponential constant 1.031×108 s-1.The function,f（α）=2（1-α）3/2,can describe the dissolution of diaspore sample in sodium hydroxide solution.The calculated results of kinetic parameters are apparent activation energy of 73.858 kJ/mol,preexponential constant of 5.752×107 s-1 and reaction order of 1.5.展开更多
Genomic imprinting is the epigenetic phenomenon by which certain genes are expressed in a parent-of-origin-specific manner, and was first discovered in mammalian embryos. Recent studies have shown that it also occurs ...Genomic imprinting is the epigenetic phenomenon by which certain genes are expressed in a parent-of-origin-specific manner, and was first discovered in mammalian embryos. Recent studies have shown that it also occurs in developing plant seeds, and is now becoming a hot topic of biology of plant seed development. According to the previous studies on imprinted genes, imprinting mechanism and their roles in plant seed development, the current progress of genomic imprinting in plant seed development was summarized and possible strategies were proposed to deal with the problems, which could provide helpful information for further research.展开更多
脑胶质瘤是颅内最常见的恶性肿瘤,复发率高,预后较差。较低级别脑胶质瘤是指2021世界卫生组织中枢神经系统肿瘤分类(World Health Organization Central Nervous System,WHO CNS)分级为2级和3级的肿瘤,较低级别脑胶质瘤的分子分型对其...脑胶质瘤是颅内最常见的恶性肿瘤,复发率高,预后较差。较低级别脑胶质瘤是指2021世界卫生组织中枢神经系统肿瘤分类(World Health Organization Central Nervous System,WHO CNS)分级为2级和3级的肿瘤,较低级别脑胶质瘤的分子分型对其治疗与预后有着重要的指导意义,因此分子分型诊断对脑胶质瘤的临床管理至关重要。分子分型诊断的金标准是病理检测,获取病理组织基因测序,但其有一定的有创性和滞后性。近年来,随着功能磁共振成像(functional MRI,fMRI)的发展,越来越多的研究明确了fMRI预测较低级别胶质瘤分子分型的价值,本文就近年来多种fMRI技术,包括扩散成像、灌注成像、酰胺质子转移成像等,对预测较低级别胶质瘤多种分子分型的研究进展作一综述,并就各种fMRI技术对不同分子分型的预测价值分别进行分析,旨在为预测较低级别胶质瘤分子分型提供影像学指标,从而达到临床精准诊治的目的。展开更多
Objective We aimed to evaluate the efficacy and safety of pemetrexed combined with erlotinib/gefitinib in advanced non-small cell lung cancer(NSCLC) patients during tyrosine kinase inhibitor(TKI) treatment. Methods Th...Objective We aimed to evaluate the efficacy and safety of pemetrexed combined with erlotinib/gefitinib in advanced non-small cell lung cancer(NSCLC) patients during tyrosine kinase inhibitor(TKI) treatment. Methods Thirty-two patients with advanced NSCLC were divided into two groups. Patients in the control group received continuous daily epidermal growth factor receptor tyrosine kinase inhibitor(EGFRTKI) treatment, and patients in the experimental group received continuous daily EGFR-TKI along with pemetrexed treatment, which was administered on day 1 at 500 mg/m2. Erlotinib(150 mg) or gefitinib(250 mg) was administered daily from day 1 to day 21, with a cycle of every 21 days. Dexamethasone, folic acid, and vitamin B12 were also administered during the treatment. The endpoint of the primary study was the disease control rate. Results The objective response rate was 21.9%(95% CI: 7.6% to 36.3%) in the control group, whereas the disease control rate was 84.4%(95% CI: 71.8% to 97.0%) in the experimental group. The median progression-free survival was 6.2(95% CI: 2.4 to 10.0). Grades 3 or 4 adverse effects of leucopenia(15.6%), neutropenia(12.5%), anemia(3.1%), and nausea or vomiting(3.1%) were found in the experimental group.Conclusion The administration of pemetrexed combined with erlotinib or gefitinib showed a higher efficacy in TKI-resistant NSCLC patients. Further, the adverse effects of this drug combination were well tolerated by the patients. Pemetrexed combined with TKI treatment might provide a satisfactory therapeutic strategy for advanced NSCLC patients after TKI treatment.展开更多
目的研究骨髓增生异常综合征（MDS）患者中表观遗传调节因子ASXL1基因的突变情况。方法在DNA水平采用聚合酶链反应（PCR）扩增产物片段直接测序分析法检测53例初发MDS患者及20名健康人ASXL1基因第12外显子突变情况，比较ASXL1突变患者...目的研究骨髓增生异常综合征（MDS）患者中表观遗传调节因子ASXL1基因的突变情况。方法在DNA水平采用聚合酶链反应（PCR）扩增产物片段直接测序分析法检测53例初发MDS患者及20名健康人ASXL1基因第12外显子突变情况，比较ASXL1突变患者与野生型患者临床及实验室特征；反转录聚合酶链反应（RT-PCR）扩增产物直接测序分析法检测ASXL1突变在mRNA水平的表达。结果在53例MDS患者中，9例（16.9 %）ASXL1基因突变。共检测出6种突变类型，包括4种移码突变（2例p.Glu635ArgfsX15、3例p.Gly646TrpfsX12、1例p.Ala640GlyfsX14、1例p.Gly790TrpfsX10）和2种无义突变（1例p.Gln1063X和1例p.Gln695X）。所有突变类型均为杂合突变，其中p.Gly790TrpfsX10和p.Gln695X为新发现突变类型。此外还检测到一种单核苷酸多态性（SNP）位点（4例p.Gly652Ser）。20名健康人中检测出pGly652Ser SNP 5名和p.Leu1173Leu SNP 1名。RT-PCR扩增产物片段直接测序可在mRNA水平检测出移码突变（p.Gly646TrpfsX12）。ASXL1突变患者初发时外周血白细胞计数、红细胞计数、血小板计数、血红蛋白、网织红细胞、中性粒细胞绝对值、外周血淋巴细胞比例、T细胞亚群、骨髓原始细胞比例、MDS分型和染色体核型分布与ASXL1野生型患者相比，差异均无统计学意义（均P〉0.05）。结论ASXL1基因在MDS患者中的突变频率较高，且可在mRNA水平检测到ASXL1基因突变。展开更多
文摘UHRF1(ubiquitin-like with PHD and Ring finger domains 1)是一种维持DNA甲基化修饰的表观遗传调控因子,在胚胎发育和肿瘤发生发展及预后中发挥重要作用。研究鉴定了受UHRF1调控的差异表达基因,并对基因参与的细胞功能、代谢途径和疾病相关通路进行分析。提取UHRF1敲低细胞(MCF-7/shRNA-UHRF1)和对照组细胞(MCF-7/shRNA-Scramble)的RNA进行RNA-Seq测序,利用DESeq2软件对差异表达基因进行鉴定,并通过qRTPCR对部分基因进行验证。利用Gene ontology(GO)功能聚类、Kyoto Encylopedia of Genes and Genomes(KEGG)代谢通路富集分析、Disease ontology(DO)疾病聚类分析等方法分析差异基因的潜在功能。研究共鉴定出2926个受UHRF1调控的差异表达基因,与对照组相比,shRNA-UHRF1细胞中有1453个基因下调表达,1473个基因上调表达。GO和KEGG分析显示,差异表达基因主要参与细胞代谢、免疫调节、信号传导、心血管疾病和肿瘤发生等。DO功能富集分析显示这些基因参与癌症和神经性疾病。研究结果表明,表观遗传调控因子UHRF1介导的DNA甲基化可在转录水平上调控基因的差异表达,为UHRF1参与调控相关信号通路提供数据支持。
基金Project(2007BC13504)supported by the National Basic Research Program of ChinaProject(20050145029)supported by Research Fund for the Doctoral Program of Higher EducationProject(2005221012)supported by the Science and Technology Talents Fund for Excellent Youth of Liaoning Province,China
文摘Mechanism functions and kinetic parameters of AlOOH（boehmite or diaspore） dissolving in sodium hydroxide solution were researched.The mixture of boehmite or diaspore and caustic solution was scanned by high-pressure differential scanning calorimetry（DSC） instrument with heating rate of 10 ℃/min,and differential equation method was used to analyse the DSC curves,combining with iterative method and linear least square method.The most probable mechanism functions for both boehmite or diaspore and caustic solution reactions were logically selected from 30 types of non-isothermal kinetics differential equations,according to the calculated results obtained by Matlab program.The most probable differential mechanism function of boehmite dissolving in caustic solution is f（α）=1-α,which reveals the first-order reaction with apparent activation energy of 79.178 kJ/mol and the preexponential constant 1.031×108 s-1.The function,f（α）=2（1-α）3/2,can describe the dissolution of diaspore sample in sodium hydroxide solution.The calculated results of kinetic parameters are apparent activation energy of 73.858 kJ/mol,preexponential constant of 5.752×107 s-1 and reaction order of 1.5.
基金Supported by National Natural Science Foundation of China(31660402)Industry Technological System Construction Project of Department of Agriculture of Yunnan ProvinceFund for Workstation of Academician Guan Chunyun from Department of Science and Technology of Yunnan Province~~
文摘Genomic imprinting is the epigenetic phenomenon by which certain genes are expressed in a parent-of-origin-specific manner, and was first discovered in mammalian embryos. Recent studies have shown that it also occurs in developing plant seeds, and is now becoming a hot topic of biology of plant seed development. According to the previous studies on imprinted genes, imprinting mechanism and their roles in plant seed development, the current progress of genomic imprinting in plant seed development was summarized and possible strategies were proposed to deal with the problems, which could provide helpful information for further research.
文摘脑胶质瘤是颅内最常见的恶性肿瘤,复发率高,预后较差。较低级别脑胶质瘤是指2021世界卫生组织中枢神经系统肿瘤分类(World Health Organization Central Nervous System,WHO CNS)分级为2级和3级的肿瘤,较低级别脑胶质瘤的分子分型对其治疗与预后有着重要的指导意义,因此分子分型诊断对脑胶质瘤的临床管理至关重要。分子分型诊断的金标准是病理检测,获取病理组织基因测序,但其有一定的有创性和滞后性。近年来,随着功能磁共振成像(functional MRI,fMRI)的发展,越来越多的研究明确了fMRI预测较低级别胶质瘤分子分型的价值,本文就近年来多种fMRI技术,包括扩散成像、灌注成像、酰胺质子转移成像等,对预测较低级别胶质瘤多种分子分型的研究进展作一综述,并就各种fMRI技术对不同分子分型的预测价值分别进行分析,旨在为预测较低级别胶质瘤分子分型提供影像学指标,从而达到临床精准诊治的目的。
基金Supported by a grant from the Postdoctoral Science Foundation of China(No.2012M512119)
文摘Objective We aimed to evaluate the efficacy and safety of pemetrexed combined with erlotinib/gefitinib in advanced non-small cell lung cancer(NSCLC) patients during tyrosine kinase inhibitor(TKI) treatment. Methods Thirty-two patients with advanced NSCLC were divided into two groups. Patients in the control group received continuous daily epidermal growth factor receptor tyrosine kinase inhibitor(EGFRTKI) treatment, and patients in the experimental group received continuous daily EGFR-TKI along with pemetrexed treatment, which was administered on day 1 at 500 mg/m2. Erlotinib(150 mg) or gefitinib(250 mg) was administered daily from day 1 to day 21, with a cycle of every 21 days. Dexamethasone, folic acid, and vitamin B12 were also administered during the treatment. The endpoint of the primary study was the disease control rate. Results The objective response rate was 21.9%(95% CI: 7.6% to 36.3%) in the control group, whereas the disease control rate was 84.4%(95% CI: 71.8% to 97.0%) in the experimental group. The median progression-free survival was 6.2(95% CI: 2.4 to 10.0). Grades 3 or 4 adverse effects of leucopenia(15.6%), neutropenia(12.5%), anemia(3.1%), and nausea or vomiting(3.1%) were found in the experimental group.Conclusion The administration of pemetrexed combined with erlotinib or gefitinib showed a higher efficacy in TKI-resistant NSCLC patients. Further, the adverse effects of this drug combination were well tolerated by the patients. Pemetrexed combined with TKI treatment might provide a satisfactory therapeutic strategy for advanced NSCLC patients after TKI treatment.
文摘目的研究骨髓增生异常综合征（MDS）患者中表观遗传调节因子ASXL1基因的突变情况。方法在DNA水平采用聚合酶链反应（PCR）扩增产物片段直接测序分析法检测53例初发MDS患者及20名健康人ASXL1基因第12外显子突变情况，比较ASXL1突变患者与野生型患者临床及实验室特征；反转录聚合酶链反应（RT-PCR）扩增产物直接测序分析法检测ASXL1突变在mRNA水平的表达。结果在53例MDS患者中，9例（16.9 %）ASXL1基因突变。共检测出6种突变类型，包括4种移码突变（2例p.Glu635ArgfsX15、3例p.Gly646TrpfsX12、1例p.Ala640GlyfsX14、1例p.Gly790TrpfsX10）和2种无义突变（1例p.Gln1063X和1例p.Gln695X）。所有突变类型均为杂合突变，其中p.Gly790TrpfsX10和p.Gln695X为新发现突变类型。此外还检测到一种单核苷酸多态性（SNP）位点（4例p.Gly652Ser）。20名健康人中检测出pGly652Ser SNP 5名和p.Leu1173Leu SNP 1名。RT-PCR扩增产物片段直接测序可在mRNA水平检测出移码突变（p.Gly646TrpfsX12）。ASXL1突变患者初发时外周血白细胞计数、红细胞计数、血小板计数、血红蛋白、网织红细胞、中性粒细胞绝对值、外周血淋巴细胞比例、T细胞亚群、骨髓原始细胞比例、MDS分型和染色体核型分布与ASXL1野生型患者相比，差异均无统计学意义（均P〉0.05）。结论ASXL1基因在MDS患者中的突变频率较高，且可在mRNA水平检测到ASXL1基因突变。
